Pasithea Therapeutics Corp. filings document a clinical-stage biotechnology issuer with Nasdaq-listed common stock and warrants. The company’s 8-K reports cover executive appointments, Regulation FD communications, shareholder voting matters, equity incentive plan approvals, Nasdaq continued-listing compliance and other material events.
Pasithea’s registration statements describe securities offerings, capital structure, emerging growth company status and risk disclosures related to biotechnology research and development. Its filings also identify the company’s Delaware incorporation, Miami Beach executive office, common stock under KTTA and warrants under KTTAW.
Pasithea Therapeutics Corp. reported that Chief Executive Officer Tiago Marques received a stock option grant covering 1,756,069 shares of common stock. The option has an exercise price of $0.841 per share and expires on April 30, 2036.
According to the grant terms, 33% of the underlying shares vest on the one-year anniversary of the grant date, with the remaining shares vesting in equal quarterly installments over the following two years, as long as he remains in continuous service. All unvested shares fully vest upon a Change in Control under the company’s 2023 Stock Incentive Plan. Vested options may generally be exercised for up to three years after termination of continuous service, other than for cause.
Pasithea Therapeutics Corp. director Lawrence Steinman received a grant of stock options as part of equity compensation. The award covers 152,783 stock options for common stock with an exercise price of $0.841 per share and an expiration date in 2036.
These options vest in full on the one-year anniversary of the grant date if he remains a director through that date, and will fully vest earlier upon a Change in Control as defined in the company’s 2023 Stock Incentive Plan.
Pasithea Therapeutics Corp. director Simon Dumesnil received a grant of stock options covering 152,783 shares of common stock. The options have an exercise price of $0.841 per share and were awarded as compensation under the company’s 2023 Stock Incentive Plan.
The options vest in full on the one-year anniversary of the grant date if he remains a director, and will fully vest earlier upon a defined Change in Control. Following this grant, Dumesnil holds 152,783 derivative securities representing rights to acquire common shares, with the options scheduled to expire on April 30, 2036.
Pasithea Therapeutics Corp. reported that its Chief Financial Officer, Daniel H. Schneiderman, received a grant of stock options covering 1,129,323 shares of common stock. The options have an exercise price of $0.8410 per share and expire in 2036.
According to the company’s 2023 Stock Incentive Plan, 33% of the underlying shares vest on the one-year anniversary of the grant date, with the remaining shares vesting in equal quarterly installments over the following two years, assuming continuous service. The options fully vest upon a Change in Control as defined in the plan, and vested options may generally be exercised for up to three years after termination of continuous service other than for cause.
Pasithea Therapeutics Corp. granted Chief Medical Officer Kartik Krishnan a stock option to acquire 1,129,323 shares of common stock at an exercise price of $0.841 per share. This is a compensation-related award, not an open-market purchase or sale.
The option was granted under the company’s 2023 Stock Incentive Plan. 33% of the underlying shares vest on the one-year anniversary of the grant date, and the remaining shares vest in equal quarterly installments over the following two years, subject to continued service. All shares underlying the option fully vest upon a Change in Control as defined in the plan.
Vested and exercisable shares may be exercised for up to three years after termination of continuous service, except in the case of termination for Cause. Following this grant, Krishnan’s reported derivative holdings from this option total 1,129,323 option shares.
Pasithea Therapeutics Corp. director Emer Leahy received a stock option grant covering 152,783 shares of common stock. The option was awarded under the company’s 2023 Stock Incentive Plan with an exercise price of $0.841 per share and expires on April 30, 2036.
The underlying 152,783 shares will vest in full on the one-year anniversary of the grant date if Leahy remains a director through that date. The shares also fully vest upon a Change in Control as defined in the plan. After this grant, Leahy holds 152,783 options directly.
Pasithea Therapeutics Corp. director Alfred J. Novak received a grant of stock options covering 152,783 shares of common stock. The options have an exercise price of $0.8410 per share and were awarded under the company’s 2023 Stock Incentive Plan.
The options vest in full on the one-year anniversary of the grant date if Novak continues to serve as a director through that date. The award will also fully vest upon a Change in Control, as defined in the plan, providing additional equity-based compensation tied to his board service.
Pasithea Therapeutics Corp. filed an initial Form 3 for Kartik Krishnan, who serves as Chief Medical Officer. The filing establishes his status as an officer and a reportable insider of the company but does not list any share holdings or recent transactions.
Pasithea Therapeutics Corp. appointed Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer effective May 1, 2026. He will lead clinical development and medical strategy as the company advances its PAS-004 MEK inhibitor program in neurofibromatosis type 1 and other indications.
Under an Executive Employment Agreement dated April 3, 2026, Dr. Krishnan receives an initial $500,000 base salary and is eligible for an annual discretionary bonus of up to 40% of salary, plus participation in benefit plans. On May 1, 2026, the board granted him options to purchase 1,129,323 shares at an exercise price of $0.841 per share, alongside sizable option grants to the CEO, CFO, other employees and non‑employee directors, with multi‑year vesting and full vesting upon a Change in Control.
Pasithea Therapeutics Corp. ownership disclosure: institutional holder Funicular Funds, LP (and related entities Cable Car Capital, LP and Jacob Ma-Weaver) reports beneficial ownership of 1,839,512 shares of Common Stock, representing 7.4% of the class based on 24,939,948 shares outstanding as reported on the issuer's Form 10-K filed March 30, 2026.
The filing lists sole voting and dispositive power for each reporting person over the same 1,839,512 shares and discloses the reporting relationships between Funicular Funds, Cable Car Capital, LP, and Jacob Ma-Weaver.